drugset / Trial / NCT02174861

A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

NCT02174861

Phase 2 Completed 609 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

To assess the long-term safety and efficacy of erenumab.

Timeline

Start
2014-06-30
Primary completion
2017-05-26
Completion
2017-05-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Erenumab Monoclonal antibody 70 mg Subcutaneous
Subject Erenumab Monoclonal antibody 140 mg Subcutaneous

Indications

No indication recorded.